Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and provide more effective options. Here are some key details about the study:
- The treatment involves a unique combination of therapies that have not been widely used together before.
- Patients will receive a specific regimen that includes both established and novel agents, which may enhance the effectiveness of the treatment.
- The study is designed to evaluate how well this combination works in managing the disease and improving patients' quality of life.
- Researchers are looking at various factors, including how the treatment affects the disease's progression and any potential side effects.
- This study includes a diverse group of participants, which may help in understanding how different patients respond to the treatment.
- By focusing on a combination approach, the study aims to address the challenges faced by patients who have limited options with current therapies.
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
